WO2012050370A3 - Composition for preventing or treating rheumatoid arthritis containing a gamma secretase inhibitor as an active ingredient - Google Patents

Composition for preventing or treating rheumatoid arthritis containing a gamma secretase inhibitor as an active ingredient Download PDF

Info

Publication number
WO2012050370A3
WO2012050370A3 PCT/KR2011/007611 KR2011007611W WO2012050370A3 WO 2012050370 A3 WO2012050370 A3 WO 2012050370A3 KR 2011007611 W KR2011007611 W KR 2011007611W WO 2012050370 A3 WO2012050370 A3 WO 2012050370A3
Authority
WO
WIPO (PCT)
Prior art keywords
secretase inhibitor
gamma secretase
reduces
rheumatoid arthritis
preventing
Prior art date
Application number
PCT/KR2011/007611
Other languages
French (fr)
Korean (ko)
Other versions
WO2012050370A2 (en
Inventor
조동규
박종성
Original Assignee
성균관대학교산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020110100981A external-priority patent/KR101330184B1/en
Application filed by 성균관대학교산학협력단 filed Critical 성균관대학교산학협력단
Publication of WO2012050370A2 publication Critical patent/WO2012050370A2/en
Publication of WO2012050370A3 publication Critical patent/WO2012050370A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to a composition for preventing or treating rheumatoid arthritis containing a gamma secretase inhibitor as an active ingredient. The gamma secretase inhibitor according to the present invention reduces the extent of arthritis induction and reduces the inflow of inflammatory cells into the knee joint, in a dose-dependent fashion, and also reduces the amount of cytokines and chemokines, and reduces the amount of expression of NICD (notch intracellular domain). Consequently, the gamma secretase inhibitor according to the present invention can be used as a medicinal product and a functional health food which is useful in the prevention or treatment of rheumatoid arthritis, since it regulates the activation, differentiation and growth of immune cells and hence has an outstanding effect in suppressing the production of NICD which plays a highly important role in notch signal transmission whereby inflammatory reactions occur.
PCT/KR2011/007611 2010-10-15 2011-10-13 Composition for preventing or treating rheumatoid arthritis containing a gamma secretase inhibitor as an active ingredient WO2012050370A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR20100100716 2010-10-15
KR10-2010-0100716 2010-10-15
KR1020110100981A KR101330184B1 (en) 2010-10-15 2011-10-05 Composition comprising gamma-secretase inhibitor for preventing or treating rheumatoid arthritis
KR10-2011-0100981 2011-10-05

Publications (2)

Publication Number Publication Date
WO2012050370A2 WO2012050370A2 (en) 2012-04-19
WO2012050370A3 true WO2012050370A3 (en) 2012-12-06

Family

ID=45938806

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2011/007611 WO2012050370A2 (en) 2010-10-15 2011-10-13 Composition for preventing or treating rheumatoid arthritis containing a gamma secretase inhibitor as an active ingredient

Country Status (1)

Country Link
WO (1) WO2012050370A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115364282A (en) * 2022-09-05 2022-11-22 东莞市人民医院 Double-function blood vessel support and preparation method thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050054633A1 (en) * 2003-09-09 2005-03-10 Alexander Flohr Malonamide derivatives
WO2009087130A1 (en) * 2008-01-11 2009-07-16 F. Hoffmann-La Roche Ag Use of a gamma-secretase inhibitor for treating cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050054633A1 (en) * 2003-09-09 2005-03-10 Alexander Flohr Malonamide derivatives
WO2009087130A1 (en) * 2008-01-11 2009-07-16 F. Hoffmann-La Roche Ag Use of a gamma-secretase inhibitor for treating cancer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LUISTRO, LEOPOLDO ET AL.: "Preclinical Profile of a Potent gamma-Secretase Inhibitor Targeting Notch Signaling with In vivo Efficacy and Pharmacodynamic Properties", CANCER RESEARCH, vol. 69, no. 19, 22 September 2009 (2009-09-22), pages 7672 - 7680 *

Also Published As

Publication number Publication date
WO2012050370A2 (en) 2012-04-19

Similar Documents

Publication Publication Date Title
EP4230623A3 (en) Pyridine compounds as allosteric shp2 inhibitors
CA3148745A1 (en) Kras g12d inhibitors
WO2012112777A3 (en) Biosynthesis of human milk oligosaccharides in engineered bacteria
JO3416B1 (en) Antimicrobial compositions and related methods of use
GEP20207158B (en) Amide-substituted pyridinyltriazole derivatives and uses thereof
PH12019500714A1 (en) Antiseptic-tolerant lactic acid bacteria
MX346458B (en) Probiotic composition for oral health.
MX2012000827A (en) Particles incorporating antimicrobial agents.
UA109876C2 (en) Composition containing bifidobacterium longum cncm i-2618 for use in treatment or prevention of disorders related to immune system
WO2011025286A3 (en) Lipoteichoic acid-derived glycolipids, and compositions comprising same
MX2012013703A (en) Modified c-3 betulinic acid derivatives as hiv maturation inhibitors.
MX2014011827A (en) 1,3,4-OXADIAZOLE AND 1,3,4-THIADIAZOLE ß-LACTAMASE INHIBITORS.
EP1941892A3 (en) Anti-allergy lactic acid bacteria
MX2010007011A (en) Composition for human and/or animal nutrition, uses thereof and yeasts.
SG184347A1 (en) Non-nucleoside reverse transcriptase inhibitors
CA2817217A1 (en) Powdered cereal compositions comprising non-replicating probiotic microorganisms
WO2012091440A3 (en) Composition for improvement, treatment and prevention of gastrointestinal motility disorders
WO2011159129A3 (en) Novel rhodanine derivatives, method for preparing same, and pharmaceutical composition for the prevention or treatment of aids containing the rhodanine derivatives as active ingredients
WO2008057300A3 (en) Trpvi antagonists and uses thereof
GB201200858D0 (en) Prebiotic powder composition and uses thereof
WO2011149301A3 (en) A composition comprising the extract of physalis alkekengi var. francheti hort as an active ingredient for preventing and treating inflammatory diseases
UA107673C2 (en) Antioxidant composition
MX2013004371A (en) Cysteine and food intake.
WO2021046315A3 (en) Inhibitors of encephalitic alphaviruses
MX2015014309A (en) Taste modulator and method of use thereof.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11832757

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11832757

Country of ref document: EP

Kind code of ref document: A2